French regulator fines Novo, Lilly over weight loss ad campaigns
As competition mounts in the red-hot market for weight loss drugs, France’s medicines regulator fined Novo Nordisk approximately…
Pharmalittle: FDA push for trial transparency, Novo-OpenAI deal
Rise and shine, everyone, another busy day is on the way. And it is getting off to a…
Eli Lilly’s obesity pill approved by FDA, setting up competition with Novo Nordisk
Eli Lilly’s obesity pill was approved by the Food and Drug Administration on Wednesday, setting it up for…
Pharmalittle: Novo boosts consumer focus, FDA okays gene therapy
And so, another working week will soon draw to a close. Not a moment too soon, yes? This…
Novo Nordisk’s high-dose Wegovy approved in the U.S.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval, the company said Thursday, providing…
Novo Nordisk warned by FDA for failure to report drug side effects
Novo Nordisk received a warning from the U.S. Food and Drug Administration for failing to report suspected incidents…
Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales
Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter…
Wegovy, Ozempic shots could be made for as little as $3 a month
Generic versions of Novo Nordisk’s blockbuster Wegovy and Ozempic medications could be mass produced for about $3 per…
Novo’s obesity drug CagriSema falls short in trial versus Zepbound
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Novo Nordisk strikes deal with startup to develop oral obesity, diabetes drugs
The rivalry between the two pharmaceutical giants that dominate the market for weight loss medicines intensified Wednesday when one…
Despite Novo Nordisk price cut, not everyone will pay less for Wegovy
Novo Nordisk made headlines Tuesday by announcing it would slash the list prices of its GLP-1 drugs and…
As China’s drug industry races ahead, its GLP-1 race is accelerating, too
For American and European drugmakers, the story of China today is one of a fast-developing market — one…